<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001075</url>
  </required_header>
  <id_info>
    <org_study_id>TJ107001STM101</org_study_id>
    <nct_id>NCT04001075</nct_id>
  </id_info>
  <brief_title>Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I/IIa, Open-label, Dose-Escalation and Dose Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part study to investigate the safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of TJ107 in Chinese patients with advanced solid tumors. Approximately a&#xD;
      total of 36 ~ 60 patients will be enrolled into the dose escalation cohorts (Part A), and&#xD;
      expansion cohorts (Part B).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities</measure>
    <time_frame>28days after first dose</time_frame>
    <description>Safety and tolerability of TJ107. Incidence of dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Safety and tolerability of TJ107. Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Safety and tolerability of TJ107. Incidence of serious adverse events by National Cancer Institute Common Terminology Criteria for Adverse Events(CI CTCAE 5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Maximum tolerated dose (MTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum effective dose</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Maximum effective dose (MED)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recommended phase II dose</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Recommended phase II dose (RP2D)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumord</condition>
  <arm_group>
    <arm_group_label>TJ107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ107</intervention_name>
    <description>Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period</description>
    <arm_group_label>TJ107</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged at least 18 years old;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~2;&#xD;
&#xD;
          -  Patients must have histological or cytological confirmation of advanced solid tumors&#xD;
             that is refractory to standard therapy or for which there is no standard available&#xD;
             therapy;&#xD;
&#xD;
          -  Predicted life expectancy ≥3 months;&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function;&#xD;
&#xD;
          -  Patients at reproductive age should take adequate contraceptive measures while on&#xD;
             study drug and for 6 months following the last dose of study drug.&#xD;
&#xD;
          -  Patients should have the ability and willingness to comply with the study and follow&#xD;
             up. And patients must be able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have experienced a Grade 3 or higher toxicity related to prior&#xD;
             immunotherapy.&#xD;
&#xD;
          -  Patients who are still receive anti-tumor therapy such as radiotherapy, chemotherapy,&#xD;
             targeted therapy, endocrine therapy, or other clinical trials from 4 weeks prior to&#xD;
             the first dose, or patients who have not recovered from previous toxicity to level 1.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients who are drug-dependent or have a history of substance abuse or psychonosema&#xD;
             history.&#xD;
&#xD;
          -  Have been vaccinated within 4 weeks of study dosing, with the exception of licensed&#xD;
             intranasal or intramuscular influenza vaccine during study&#xD;
&#xD;
          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation&#xD;
&#xD;
          -  Positive laboratory test for HBsAg with HBV DNA ≥ 100 IU/mL, or positive laboratory&#xD;
             test for HCV.&#xD;
&#xD;
          -  Prior treatment with immune checkpoint inhibitors, immunomodulatory mAbs, and/or&#xD;
             mAb-derived therapies is allowed provided that at least 3 months or 5 half-lives of&#xD;
             the drug, whichever is longer, have elapsed from the last dose.&#xD;
&#xD;
          -  Uncontrolled concurrent illness.&#xD;
&#xD;
          -  Major surgery procedure (excluding diagnostic surgery) within 4 weeks of the first&#xD;
             dose of study drug.&#xD;
&#xD;
          -  Patients with a history of treated CNS metastases.&#xD;
&#xD;
          -  Other psychiatric illness/social situations that would limit compliance with the study&#xD;
             requirements decided by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The sixth Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of the Medical</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

